



**Pharmacodynamic Biomarkers for HTT-Lowering Therapies:  
A White Paper**

**Date of release: April 2015**

**Version edited: July 2017**

**Huntingtin-Lowering Biomarker Project Team:**

Douglas Macdonald\*, Beth Borowsky\*, Jonathan Bard, Roger Cachepe, Larry Park, John Wityak,  
Valentina Dilda, Andrew Wood, and Ladislav Mrzljak

\*Co-leaders

**Huntingtin-Lowering Biomarker Task Force Committee Members:**

Cristina Sampaio, Robert Pacifici, Ethan Signer, Ignacio Munoz-Sanjuan, Celia Dominguez, Beth  
Borowsky, Cheryl Fitzer-Attas, Douglas Macdonald, and Thomas Vogt



This work is licensed under a [Creative Commons Attribution-ShareAlike 3.0 United States License](https://creativecommons.org/licenses/by-sa/3.0/).



## TABLE OF CONTENTS

<b>EXECUTIVE SUMMARY .....</b>	<b>5</b>
<b>1. INTRODUCTION.....</b>	<b>9</b>
<b>1.1 Huntington’s disease and huntingtin .....</b>	<b>9</b>
<b>1.2 Overview of HTT-lowering interventions .....</b>	<b>9</b>
<b>1.3 Pharmacodynamic biomarkers .....</b>	<b>11</b>
<b>2. TASK FORCE METHODOLOGY .....</b>	<b>13</b>
<b>2.1 CHDI Huntingtin-Lowering Biomarkers Task Force .....</b>	<b>13</b>
<b>2.2 Task Force objective .....</b>	<b>13</b>
<b>2.3 Criteria for an appropriate biomarker.....</b>	<b>13</b>
2.3.1 Peripheral versus central biomarkers.....	15
<b>3. METHODOLOGY FOR EVALUATING PHARMACODYNAMIC BIOMARKER DOMAINS .....</b>	<b>16</b>
<b>3.1 Prioritization of biomarker domains for study .....</b>	<b>16</b>
<b>3.2 Analytic methodology .....</b>	<b>17</b>
<b>3.3 Clinical studies .....</b>	<b>17</b>
3.3.1 Populations under study.....	18
<b>3.4 Proof-of-principle studies in animal models.....</b>	<b>18</b>
3.4.1 Selection of animal models for use in PoP studies .....	18
<b>4. OVERVIEW OF BIOMARKER STUDIES .....</b>	<b>21</b>
<b>4.1 HTT protein measurement in CSF .....</b>	<b>21</b>
4.1.1 Methodology .....	21
4.1.2 Clinical evaluation.....	22
4.1.3 Preclinical validation.....	24
4.1.4 HTT protein measurement in CSF biomarker domain status .....	25
<b>4.2 PET and microPET imaging.....</b>	<b>26</b>
4.2.1 Methodology .....	26
4.2.2 Clinical evaluation.....	27
4.2.3 Preclinical validation .....	29
4.2.4 PET imaging (other than HTT) biomarker domain status .....	32
4.2.5 HTT PET imaging biomarker domain status.....	32
<b>4.3 Quantitative EEG .....</b>	<b>33</b>

4.3.1 Methodology .....	33
4.3.2 Clinical evaluation .....	33
4.3.3 Preclinical validation .....	34
4.3.4 qEEG biomarker domain status .....	35
<b>4.4 Proteomics: static and kinetic.....</b>	<b>36</b>
4.4.1 Methodology .....	36
4.4.2 Clinical evaluation .....	37
4.4.3 Preclinical validation .....	38
4.4.4 Proteomics static biomarker domain status.....	39
4.4.5 Proteomics dynamic biomarker domain status.....	39
<b>4.5 Magnetic Resonance Spectroscopy (MRS) imaging .....</b>	<b>40</b>
4.5.1 Methodology .....	40
4.5.2 Clinical evaluation .....	41
4.5.3 Preclinical validation .....	42
4.5.4 MRS biomarker domain status .....	42
<b>5. CLOSING COMMENTS.....</b>	<b>44</b>
<b>6. REFERENCES.....</b>	<b>45</b>

## EXECUTIVE SUMMARY

### *Audience and objective*

The purpose of this white paper is to inform the Huntington's disease (HD) community, including key stakeholders involved in the development of huntingtin protein (HTT)-lowering therapeutics, about the strategy, timelines and current study status of the CHDI Foundation HTT-Lowering Biomarker Initiative.

### *Background*

HTT lowering is a key therapeutic strategy for HD. Reducing the amount of the disease-causing expanded HTT protein in HD-affected brains is predicted to reduce signs and symptoms and slow the progression of the disease.<sup>1,2</sup> Several approaches are being developed to lower HTT, including the use of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), and gene therapy using viral delivery of microRNAs (miRNAs), short hairpin RNAs (shRNAs), and zinc-finger repressor proteins (ZFPs).<sup>2-10</sup> In addition, HTT-lowering pharmacodynamic biomarkers are being studied in both preclinical HD models and in observational clinical studies to enable the translation of such outcome measures to the clinic.

Our aim is to develop and validate outcome assessment measures to confirm whether the delivery of an HTT-lowering therapy to the CNS does indeed lower the amount of HTT protein in HD patients.

### *Overview*

Pharmacodynamic biomarkers are considered vital to confirm that a therapeutic agent reaches its intended target and has a biological effect. CHDI has committed to developing pharmacodynamic biomarkers of HTT lowering to support HTT-lowering clinical development programs. We began this process by establishing a Task Force and holding a series of several workshops with internal and external experts to assess the landscape of potential biomarkers that could be developed in a timeframe consistent with the anticipated timing of clinical trials. We then prioritized several classes (referred to as 'domains') of biomarkers by both their scientific rationale and their likely timeline to the clinic, and began evaluating these in preclinical HD models.

### *Methodology*

We are currently focusing on three domains:

- 1) Static and dynamic CSF markers, in particular HTT protein quantification
- 2) Neuroimaging, including PET and MRS

### 3) Physiological measures, including qEEG

We are evaluating these domains using a consistent methodology that includes evaluation for clinical suitability (in observational studies) and preclinical proof-of-principle (PoP) validation.

While the scope of work under the auspices of the CHDI Huntingtin-lowering Biomarkers Task Force is focused exclusively on identifying pharmacodynamic biomarkers of HTT lowering, it should be noted that the Foundation has parallel efforts committed to identifying biomarkers of disease progression and disease state. Those biomarkers will be critical for PoP and efficacy trials. Many of the same domains of biomarkers that we have been evaluating as potential disease progression or state biomarkers—such as MRS, PET, and qEEG—are now also being evaluated as potential pharmacodynamic markers. While it is conceivable that a given domain of biomarker could have dual applications, it is important to evaluate each biomarker specifically for its intended use and context. Accordingly, the focus of this white paper will be on pharmacodynamic biomarkers of HTT lowering, but relevant information already obtained regarding the profile of some biomarkers in the course of the disease may also be highlighted.

## Summary Results

	HTT Protein in CSF	PET Imaging	HTT PET Imaging	CSF Proteomics: Static	CSF Proteomics: Kinetic	qEEG	MRS
<i>Biological plausibility</i>	HIGH	MODERATE	HIGH	MODERATE	MODERATE	MODERATE	MODERATE
<i>Measurable in humans</i>	YES	YES	UNKNOWN	YES	YES	YES	YES
<i>Technological feasibility</i>	YES	YES	STUDIES ONGOING	YES	YES	YES	YES
<i>Repeatable within subjects</i>	YES	YES	YES	YES	YES	YES	YES
<i>Reliably measured in HDGECs</i>	STUDIES ONGOING	STUDIES ONGOING	TBD	STUDIES ONGOING	TBD	YES	YES
<i>Signal metrics: dynamic range, variance</i>	STUDIES ONGOING	STUDIES ONGOING	STUDIES ONGOING	STUDIES ONGOING	TBD	YES	YES
<i>Measurable in HD animal models</i>	YES	YES	STUDIES ONGOING	STUDIES ONGOING	YES	YES	YES
<i>PoP: Changes in response to central lowering of HTT in animal models</i>	STUDIES ONGOING	YES	STUDIES PLANNED	STUDIES PLANNED	TBD	STUDIES PLANNED	STUDIES ONGOING
<i>Changes in response to an HTT-lowering intervention in HDGECs</i>	TBD	TBD	TBD	TBD	TBD	TBD	TBD

**Legend:** Assessment of the seven prioritized biomarker domains (top) according to the nine established criteria (left). TBD = to be determined.

## ABBREVIATIONS

ASOs	Antisense oligonucleotides
BAC HD rat	BAC transgenic rat model of HD
BDNF	Brain-derived neurotrophic factor
BP <sub>ND</sub>	Binding potential
CSF	Cerebrospinal fluid
CNS	Central nervous system
GP	Globus pallidus
HD	Huntington's disease
HDGEC	Huntington's disease gene expansion carrier
HTT ( <i>HTT</i> )	Huntingtin protein ( <i>gene</i> )
ICV	Intracerebroventricular (administration)
mHTT	Mutant huntingtin protein
miRNAs	MicroRNAs
MRM	Multiple reaction monitoring
MRS	Magnetic resonance spectroscopy
PET	Positron emission tomography
PoP	Proof-of-principle
Q175 HET	Q175 heterozygote knock-in mouse model of HD
Q175 HOM	Q175 homozygote knock-in mouse model of HD
qEEG	Quantitative electroencephalography
RNAi	RNA interference
RISC	RNA-induced silencing complex
SRM	Selected reaction monitoring
SNPs	Single-nucleotide polymorphisms
shRNAs	Short hairpin RNAs
siRNAs	Small interfering RNAs
TFC	Total functional capacity score
WT	Wild type
ZFPs	Zinc-finger repressor proteins



## 1. INTRODUCTION

### 1.1 Huntington's disease and huntingtin

HD is an autosomal-dominant, progressive, neurodegenerative disorder caused by an expanded trinucleotide CAG sequence in exon 1 of *HTT*, which encodes a stretch of glutamines in HTT.<sup>11</sup> HTT plays a role in a variety of cellular processes, and is expressed ubiquitously with the greatest expression found in the CNS.<sup>12</sup> The mutant polyglutamine expanded form of HTT is cytotoxic, leading to the hallmark pathology of HD, including pronounced atrophy of the striatum and other brain regions.<sup>13</sup> The temporal effect of mHTT is dependent on the number of CAG repeats in the gene, resulting in an inverse relationship between the age of motoric symptom onset and the CAG repeat size.<sup>14,15</sup>

There are no disease-modifying therapies for this neurodegenerative disease that is characterized by the development of progressive motor dysfunction, cognitive decline, and psychiatric disturbances.<sup>16,17</sup> Available treatments for HD are currently limited to the management of symptoms using drugs developed for other indications. To date, most of the potential therapeutic candidates evaluated specifically for HD have had limited success in clinical studies. At best these candidates have targeted individual pathways or mechanisms hypothesized to be downstream of the expression of mHTT, and the success of such approaches may require further elucidation of the mechanism by which mHTT causes disease. Since mHTT is the most proximal therapeutic target and may affect multiple mechanisms and downstream cellular pathways,<sup>14,18</sup> preventing or reducing the expression of mHTT (HTT lowering) is one of the most promising approaches for the treatment of HD.<sup>1,2,19</sup> At the present time, it appears that decreasing the levels of mHTT may be less likely to have unwanted side-effects and more likely to have efficacy on all aspects of the HD phenotype than therapies directed at downstream targets.<sup>20</sup>

### 1.2 Overview of HTT-lowering interventions

Several approaches are being developed to lower HTT, including antisense oligonucleotides and siRNAs, as well as gene therapy using viral delivery of miRNAs, shRNAs, and ZFPs.<sup>2-9</sup> Modulation of HTT levels at the transcriptional level has been achieved in experimental models by the use of ZFPs,<sup>5,21</sup> while at the translational level ASOs, siRNAs and miRNAs have all been used to lower HTT.<sup>3,4,8-10</sup> Approaches to increase the clearance of mHTT protein have also been addressed by several groups.<sup>22-24</sup>

These approaches can be separated into 'chemical' therapeutics, which includes ASOs, siRNAs and other small molecules, and gene therapy approaches that deliver a therapeutic by gene expression, such as ZFPs,

miRNAs or shRNAs. If the particular agent targets a sequence common to both the normal and mutant HTT allele, it is termed a “pan-lowering agent”. Alternatively, one can design allele-selective lowering agents that preferentially lower expression of the mutant rather than the normal protein. These agents would be directed towards either the expanded CAG repeat domain of the mutant allele or specific SNPs present in the mutant allele.<sup>10,25-28</sup>

ASOs are modified, single-stranded DNA molecules that are designed to be complementary to the target mRNA and form a DNA/RNA hybrid complex that is degraded by the endogenous enzyme RNase H. siRNAs are double-stranded RNA molecules that are processed by the cytoplasmic endoribonuclease enzyme Dicer and assembled into an RNA-induced silencing complex (RISC). An activated RISC binds the target mRNA, resulting in mRNA cleavage and a decrease in gene expression. Current HTT-directed ASOs and siRNAs are unable to cross the blood–brain barrier and must be delivered directly into the CNS, which results in discrete distribution limited to the specific targeted areas of the brain.<sup>19,29</sup> Therefore, the main challenge in developing ASOs and siRNAs as therapeutic agents is their delivery to the brain. The ongoing preclinical studies described in this report are necessarily based on direct infusion into the CNS, either to the brain parenchyma or into the CSF, similar to the expected administration in the clinic.

Gene therapy is the use of nucleic acids to deliver and express proteins or interfere with the expression of proteins. Example cargo constructs include miRNAs, shRNAs, and larger proteins including ZFPs.<sup>30</sup> For HTT lowering, several such agents have been developed for delivery by viral transduction into the brain parenchyma.

These novel approaches are rapidly progressing towards the clinical phases of development; however, a key barrier is the lack of appropriate pharmacodynamic biomarkers that adequately demonstrate target engagement and PoP for HTT-lowering effects. Rapid identification of appropriate biomarkers will decrease the risk of having clinical trial results that are not interpretable due to uncertainty regarding the potential clinical outcome.

### 1.3 Pharmacodynamic biomarkers

Biomarkers are now a cornerstone of the drug development process, and may combine physiological and molecular measures of disease.<sup>19,31</sup> Biomarkers are considered essential for early phase I/II clinical trials and can be categorized as *trait* (biomarkers that are stable over time), *state* (biomarkers that change with disease progression or treatment), or *pharmacodynamic* (sometimes referred to as mechanism-of-action markers).<sup>19</sup>

Biomarkers allow drug developers to make good and timely decisions regarding the clinical development of an investigational drug. If a therapeutic candidate does not affect a relevant biomarker, ideally in a dose-dependent manner, this will call into question whether to continue the development of the compound. The earlier this happens, the better, as this will save the financial and human expense of late-phase clinical trials and encourage more effort in the design of alternative candidates or dosing strategies.

In the absence of evidence that an investigational treatment actually reaches its intended target and has a mechanistic effect, it is impossible to fully interpret trial results. Consider, for example, a phase I trial of a potential HTT-lowering therapy that ends without signs of undue toxicity and allows a conclusion of good tolerability. This result is only trustworthy regarding potential intervention-specific effects if the therapeutic agent actually reached its intended target and lowered HTT in the brain. If it cannot be demonstrated that it did indeed lower HTT levels in the brain, then no conclusions can be made about the safety of 'on-target' HTT reduction. Such a trial can still be informative for issues related to the technique of administration, but not beyond.

In a typical clinical development plan, safety and tolerability are first assessed in healthy volunteers in phase I studies. Maximum tolerated doses can be determined by escalating dosage until adverse effects are seen. Demonstration of target engagement and PoP then follow in phase II trials in patients. However, as with many target-specific oncology interventions,<sup>32-34</sup> human phase I HTT-lowering trials are expected to be conducted in patients rather than in healthy volunteers. In such trials, the key phase I question the trial is addressing is the on-mechanism safety of target engagement rather than systemic toxicity.<sup>32-34</sup> We consider it very important that phase I trials of HTT-lowering interventions attempt to demonstrate target engagement whenever possible. As biomarkers with appropriate supporting data become available, phase I trials should be designed to achieve at least a percentage of HTT reduction monitored by the biomarker response. This would replace the practice of dosing on the basis of drug concentration alone.

This white paper focuses on evaluating potential pharmacodynamic biomarkers of HTT lowering that can be used to confirm that a therapeutic agent reaches its intended target and has a biological effect. Current biomarker approaches under preclinical and clinical evaluation include the use of molecular, imaging, and electrophysiological outcomes. One or more of these pharmacodynamic markers will be essential tools for demonstrating that the delivery of an HTT-lowering therapy does, in fact, lower the amount of HTT in the brains of HD patients.

## 2. TASK FORCE METHODOLOGY

### 2.1 CHDI Huntingtin-Lowering Biomarkers Task Force

The CHDI Huntingtin-Lowering Biomarkers Task Force was initiated to accelerate the process of identifying pharmacodynamic biomarkers of HTT lowering by conducting a systematic and pragmatic approach to biomarker development. To achieve this, the Task Force brings together expert members from CHDI and collaborators from the academic, pharmaceutical, and biotech sectors.

A first step for the Task Force was to take an overview of current biomarker development, and define the essential criteria for an HTT-lowering pharmacodynamic biomarker. Next, a thorough evaluation and prioritization was made of the potential domains of biomarkers that could be explored in animal models and humans. We then developed a coordinated and streamlined process for evaluating each of these prioritized domains. This white paper provides an overview of each of the identified domains and their current status.

### 2.2 Task Force objective

The main objective of the Task Force is the identification and/or development of one or more pharmacodynamic biomarkers that can be used to measure changes in response to HTT-lowering interventions in HD patients. With the rapid advancement of such therapeutic approaches, it is critical that this biomarker development advance within a short time frame so that it can be integrated into the design of clinical trials now being planned. As such, the goal is to have reliable pharmacodynamic biomarkers ready for use in trials of HTT-lowering therapies due to start in the near future. We acknowledge that not all biomarkers will be applicable to all HTT-lowering agents; nevertheless, we have focused on the identification of up to four potential strategies or candidates that can be actively pursued.

### 2.3 Criteria for an appropriate biomarker

The Task Force has developed the following set of criteria to define pharmacodynamic biomarkers that would be useful in the context of clinical trials. Considerations for criteria included both the merits of the technique itself as well as the informative value of the biomarker.

## **Biomarker criteria**

<p><b>1. <i>Biological plausibility:</i></b> <i>The connection between a putative reduction in the levels of HTT and the outcome measurement (biomarker readout) should be biologically plausible.</i></p> <p>Biological plausibility is a requirement in the causality relationship. It is a matter of judgment, taking into account the knowledge that exists in the literature regarding the disease pathophysiology and the conceptual basis of the measurement method. For pharmacodynamic biomarkers, it is important to consider the degree of distance from the original disease insult.</p>
<p><b>2. <i>Technological feasibility:</i></b> <i>The technology should be feasible in humans and animal models.</i></p> <p>The technology should already exist or be easily adaptable to measure the biomarker in both HD animal models and in human HD patients.</p>
<p><b>3. <i>Measurable in humans:</i></b> <i>It must be possible to measure the biomarker in humans.</i></p> <p>This informed our decision to focus on non-invasive approaches.</p>
<p><b>4. <i>Repeatable within subjects:</i></b> <i>The biomarker should be amenable to repeated measurements.</i></p> <p>Repeated biomarker measurements will most likely need to be made over weeks or months in a clinical trial, both before and after treatment, so it is important to consider biomarkers that can be repeatedly measured within individuals. Biomarkers should also demonstrate good test–retest results, giving comparable measures when administered to the same individual multiple times over days, weeks, or months.</p>
<p><b>5. <i>Reliably measured in HDGECs:</i></b> <i>The biomarker should be measurable in a reliable fashion in HD patients at stages of the disease likely to be targeted in upcoming clinical trials.</i></p> <p>Clinical studies should demonstrate that the biomarker can be reliably measured in late pre-manifest, and early- to mid-stage manifest HD.</p>
<p><b>6. <i>Signal metrics:</i></b> <i>dynamic range, variance, etc.</i></p> <p>The biomarker should be robust enough to detect any treatment-induced change. It should have a good signal-to-noise ratio, good dynamic range, and acceptable variance to be able to distinguish effects with relatively small sample sizes, and have strong inter- and intra-subject and site reliability.</p>
<p><b>7. <i>Measurable in preclinical HD models</i></b></p> <p>The biomarker must be quantifiable in HD animal models in order to conduct the critical PoP studies.</p>

**8. PoP - Changes in response to central lowering of HTT in preclinical models**

The biomarker must respond to HTT lowering in a relevant HD model (i.e., confirming PoP). An appropriate biomarker should reflect HTT lowering and not simply the delivery of the therapeutic itself (e.g., an inflammatory marker might be elevated by the therapeutic delivery). Although qualitative measurements may initially suffice, quantitative measurements that demonstrate responsiveness are preferred. When possible, there should be a demonstrated correlation of the biomarker with lowering of HTT levels.

**9. Changes in response to a HTT-lowering intervention in HDGECs**

The ultimate validation of the biomarker will occur only after successful, positive clinical trials of HTT-lowering agents have been completed.

**2.3.1 Peripheral versus central biomarkers**

The Task Force noted that by lowering HTT (WT, mutant, or both) in the CNS, there may be peripheral consequences that can be detected in blood, such as a downstream signaling molecule. This possibility may be of interest in the future, but it was agreed that the majority of efforts would be concentrated on CNS biomarkers because a change in a central marker, as compared to a peripheral marker, is more likely to reflect a change in central HTT levels.

The Task Force also noted that differences in HTT-lowering therapeutic approaches (e.g., target brain regions, modes of administration, etc.) might require different biomarkers. Some HTT-lowering agents may only be delivered selectively to modulate HTT levels in the striatum, while others might selectively target the cortex. It is therefore important to develop biomarkers specific to those brain regions. For example, phosphodiesterase (PDE) 10A expression, which is localized to the basal ganglia, is quantified using the PET ligand <sup>18</sup>F-MNI-659, which is currently under study as a striatal-specific marker of neuronal changes. Other examples are detailed in the sections below.

### 3. METHODOLOGY FOR EVALUATING PHARMACODYNAMIC BIOMARKER DOMAINS

The validation of each potential biomarker includes a variety of key steps ranging from validation of the analytic methodology to preclinical PoP studies and clinical studies to evaluate the reliability, reproducibility and repeatability of the biomarker in humans. The main steps are described below.

#### 3.1 Prioritization of biomarker domains for study

To streamline the process, the Task Force prioritized seven biomarker domains and designated CHDI Science Directors to lead each of the clinical and preclinical efforts:

<b>Biomarker Domain</b>	<b>Project Leaders</b>
<b>HTT Protein in CSF</b>	<i>Douglas Macdonald</i>
<b>PET Imaging</b>	<i>Ladislav Mrzljak &amp; Andrew Wood</i>
<b>PET Imaging HTT</b>	<i>Jonathan Bard, Celia Dominguez, &amp; Andrew Wood</i>
<b>CSF Proteomics: Static</b>	<i>Jonathan Bard</i>
<b>CSF Proteomics: Kinetic</b>	<i>Jonathan Bard &amp; Valentina Dilda</i>
<b>qEEG</b>	<i>Roger Cachope</i>
<b>MR Spectroscopy</b>	<i>Larry Park &amp; Valentina Dilda</i>

While we are taking a parallel approach to evaluate these biomarker domains, they are prioritized based on the available methodologies, preliminary data, and potential utility in upcoming clinical trials. Initially, we are focusing on HTT protein measurements in CSF, existing PET tracers (PDE10, D1, D2, and CB1 ligands), and kinetic proteomic measurements in our preclinical model studies. The second tier of studies includes other existing PET tracers for targets of interest as well as a novel HTT tracer, MRS, qEEG, and static proteomics.

The domains selected reflect the criteria listed as relevant for a pharmacodynamic biomarker and the readiness for the immediate use of the technologies. All of the biomarkers listed have available technologies with the exception of the PET imaging of HTT itself, which is still in development. Some of the biomarkers are specific to a given brain region; for example, qEEG is mainly relevant for the cortex. In other cases, it remains unclear whether the biomarker reflects HTT lowering in areas outside the compartment measured (as is the case for measuring HTT in CSF). Excluding the circumstances where there is a clear-cut specificity of use, several different biomarkers should have convergent responses.



Therefore the concurrent use of different domains is advisable. We strive to find the best combinations of biomarkers that, together, will increase our confidence that there is indeed target engagement and a pharmacodynamic response clearly attributable to the administered intervention. Using several biomarkers simultaneously implies a trade-off between the confidence regarding the outcome measured and the burden that each measurement puts on subjects.

### 3.2 Analytic methodology

Validation of the analytic methodology will be obtained (if available) from the providers of the methods, or may need to be developed and confirmed experimentally by CHDI (as is the case for HTT quantitation assays). Several of the technologies being employed, such as PET and qEEG, are in common use and are therefore readily available with international standards (and the sites where they are available are regulated and/or certified).

### 3.3 Clinical studies

A key consideration in the prioritization of biomarker domains for study was the known ability to measure the biomarker in humans. The next steps in this process are to assess the reliability, variability, and potential effect size of the prospective biomarkers in the disease state. Of course, it is not yet possible to clinically test whether a biomarker is sensitive to change induced by the intervention, since none of the interventions have yet been tested in humans. The intention is to conduct preliminary observational studies of the candidate biomarkers in the clinic that will be updated when data from the initial clinical trial can be incorporated into the validation plans.

***Current clinical studies aim to answer the following key questions:***

- 1. Can the biomarker be measured consistently in HD patients?***
- 2. Is the measurement robust enough (in terms of reliability and variability) to show a change, if one occurs, after HTT lowering?***
- 3. Is the biomarker altered by the disease (an indirect indication that the biomarker might change with HTT lowering)?<sup>1</sup>***

---

<sup>1</sup> Note that this is not a requirement for a pharmacodynamic biomarker, which by definition is intervention-related and independent of the disease. However, in the case of HTT-lowering interventions, this information might help us understand whether the biomarker is likely to be responsive to mHTT levels. HD pathogenesis is considered to be at least partially dependent on mHTT levels and, as such, disease-induced alterations in biomarker readouts can be considered an indirect indication that the biomarker might change after HTT lowering.

### 3.3.1 Populations under study

Predictive testing allows HDGECs to be identified in their premanifest phase before they develop symptoms.<sup>35</sup> While the first clinical trials of HTT-lowering therapies are expected to be in people with early-manifest disease (stages 1 and 2), we are assessing the reliability and effect size of candidate biomarkers in both premanifest and manifest HDGECs.

### 3.4 Proof-of-principle studies in animal models

PoP studies evaluate the ability of a potential biomarker to change when HTT protein is lowered in the brain of an animal model of HD. This is an extremely important step in biomarker validation since we cannot yet test the HTT-lowering interventions in HD patients.

***Current preclinical PoP studies aim to answer the following key questions:***

- 1. Can this biomarker be measured in HD animal models?***
- 2. Does the biomarker change in response to HTT lowering in a dose-<sup>2</sup> and time-dependent manner?***

#### 3.4.1 Selection of preclinical animal models for use in PoP studies

A large number of preclinical HD models are available that have a variety of mHTT constructs, including fragment transgene models, full-length artificial chromosome models, and genetic expansion knock-in models.<sup>36-40</sup> For the purposes of validating the selected HTT-lowering biomarkers, it was decided that the animal model should do the following:

- 1. Reflect the genetics of human HD.***

Use of a model containing a genocopy heterozygous knock-in with one expanded and one non-expanded HTT allele.

- 2. Exhibit measurable deficits that reflect appropriate stages of the disease.***

The primary experimental setup being employed allows the testing of the most relevant time point of intervention in phenotypic ‘manifest’ animals, as the current HTT-lowering therapies will most likely be tested first in stage 1 symptomatic HD patients.

---

<sup>2</sup> Dose and time dependence are not an absolute requirement as it may be difficult to demonstrate dose-dependency with some modalities (e.g. AAV therapies where only one dose is administered).

We have selected the Q175 knock-in heterozygote (Q175 HET) HD mouse model<sup>41,42</sup> as the primary model for our HTT-lowering biomarker validation studies. Q175 HET mice exhibit first signs of motor symptoms at 3 to 4 months of age and behavioral deficits accompanied by marked brain atrophy and brain metabolite changes by 8 months.<sup>41,42</sup> Depending on the measure, dosing will occur in 4–6 month old Q175 HET mice. We will also examine interventions at earlier stages. However, mouse models can only provide a limited amount of tissue, so we have included an additional HD model, the BAC HD transgenic rat model (BAC HD rat)<sup>43</sup>, which can provide ten times the volume of CSF compared to a mouse. BAC HD rats have an early onset and progressive HD-like phenotype including motor deficits and anxiety-related symptoms,<sup>43</sup> and this model can provide serial draws of CSF (an advantage over the mouse Q175 knock-in model), allowing for pre- and post-dosing collections.

### 3.4.2 HTT-lowering agent delivery methods

Another important consideration in the design of preclinical studies is the delivery method of the intervention. To date, all HTT-lowering agents must be delivered directly to the CNS and each agent has a specific mode of delivery that dictates biodistribution.

- *ASOs*: In rodent models, ASOs are being delivered either intraventricularly by bolus or pump/infusion resulting in distribution to the majority of the brain, or intrathecally by bolus resulting in distribution predominantly to the spinal cord and brain cortex. The latter is being employed to mimic what is expected to be the administration route and distribution of ASOs in the planned upcoming clinical trial. Furthermore, intrathecal delivery can be used in large animals (i.e., non-human primates).
- *siRNAs*: In rodent models, siRNAs are being delivered by intraparenchymal infusion into the striatum by pump resulting in a distribution that is mostly limited to that part of the basal ganglia. This somewhat mimics the expected clinical dosing paradigm using convection-enhanced delivery infusion systems as demonstrated in non-human primates.
- *Viral vectors (i.e., AAV-ZFPs, AAV-miRNAs)*: In rodent models, gene therapy approaches using viral delivery and transduction are being delivered by intraparenchymal bolus infusion into specific brain regions (i.e., striatum) resulting in distribution to the target area. This mimics what is expected in the clinic and is also applicable to large animal models (i.e., non-human primates). It is also worthwhile to note that some of these viral expression systems may be used to affect other brain regions and more distant structures, but this needs to be examined more closely. Recent reports from several groups have demonstrated intravascular peripheral dosing of viral vectors resulting in CNS exposure, and this may become a delivery option for such agents in the future.<sup>44</sup>



## 4. OVERVIEW OF BIOMARKER STUDIES

### 4.1 HTT protein measurement in CSF

The first biomarker approach considered by the Task Force is the measurement of HTT protein in the CSF compartment. This proteomic approach uses recent technological advances that enable measurement of proteins at much lower concentrations than was previously achievable. Using a novel, ultra-sensitive, single-molecule counting immunoassay (the Erenna<sup>®</sup> Immunoassay System by Singulex), CHDI and collaborators have shown in two cohorts of HD patients' CSF samples that soluble mHTT can be quantified in the femtomolar range.<sup>45,46</sup> CHDI is also developing HTT assays to detect total, full-length, fragment, and aggregated HTT to enable the profiling of HTT proteins in such biosamples. Other advanced technologies such as the Simoa HD-1 Analyzer (Quanterix) and the S-Plex platform (Meso Scale Discovery, MSD) may also provide the sensitivity required to detect low-level analytes in CSF; investigators outside of CHDI may be exploring these alternate platforms.

#### *4.1.1 Methodology*

Quantifying HTT protein in CSF may be a valuable biomarker to assess the response to HTT-lowering treatment. The Erenna<sup>®</sup> Immunoassay System represents an important advance and, in addition to quantifying mHTT in HD patient CSF samples, it has also been used to quantify mHTT in CSF from rodent HD models enabling preclinical PoP experiments. Depending on the HTT expression level in preclinical models, assays already developed on the Meso Scale Discovery platform can also be used to measure HTT proteins in such biosamples.<sup>47</sup>

*Summary of HTT assay platforms - quantifying HTT in human and rodent model CSF samples*

Assay Platform	HTT Detection	HTT in Human CSF	HTT in HD Model CSF
TR-FRET	Mutant	No	tbd
	Total	No	tbd
	Oligomeric	ND	tbd
MSD	Mutant	Prelim	YES
	Total	No	tbd
	Mouse	ND	tbd
	Full length	No	tbd
	Aggregated	ND	tbd
Singulex	Mutant	YES	YES
	Total	ND	tbd
	Full length	ND	tbd

Green = assay can be used to quantify indicated HTT species; beige = studies ongoing; red = assay does not quantify indicated HTT species; ND = not done; TBD = to be determined.

*4.1.2 Clinical evaluation*

Using the Erenna® technology described above, Edward Wild and colleagues found that mHTT is undetectable in control subjects but quantifiable in nearly all HDGECs.<sup>46</sup> Interestingly, they reported that the CSF mHTT concentration was ~3-fold higher in patients with manifest HD as compared to premanifest HD.<sup>46</sup>

While this is a promising start toward developing a pharmacodynamic biomarker for HTT lowering, there remain several potential limitations of this approach. First, the amount of HTT measured in the CSF was in the femtomolar range, close to the limit of detection of the assay, so it's still unclear whether the assay is sensitive enough to measure modest reductions in CSF mHTT levels in HD patients. Second, while it is assumed that CSF mHTT is brain-derived due to the correlation with brain-specific proteins and the lack of hemoglobin detection in the samples, a peripheral source cannot be completely ruled out, particularly because the concentration of mHTT in blood is several orders of magnitude higher than in CSF. And third, even if CSF mHTT is indeed brain derived, we do not know the relative contribution of newly synthesized mHTT versus older stores of mHTT from dying cells. Short-term exposure to a HTT-lowering treatment is likely to affect only newly synthesized mHTT, and only from regionally discrete parts of the brain, meaning that reduction of newly synthesized HTT in a restricted portion of the brain would need to lead to a

measurable decrease in the already very low levels of mHTT in CSF. With those caveats, CSF mHTT remains a highly attractive potential pharmacodynamic biomarker that needs additional evaluation.

CHDI has also partnered with University College London (UCL) to launch a clinical study called HDClarity, a collection of CSF and blood samples from HDGECs and healthy controls to enable the discovery and development of pharmacodynamic and disease progression biomarkers. Roughly 10 clinical sites in North America and Europe that participate in Enroll-HD ([www.enroll-hd.org](http://www.enroll-hd.org)) will recruit healthy controls and patients with late premanifest, early, moderate and advanced HD to complete regular clinical assessments and donate CSF and plasma for biomarker discovery and validation. A CSF consortium—consisting of CHDI, UCL, and the clinical site principal investigators—is being established to conduct a large number of CSF biomarker studies, including HDClarity. The CSF consortium will oversee access to these biosamples for various research efforts, taking into account the merits of the research proposal, ranking of priorities and rules of use for limited samples. The identification and characterization of an HTT-lowering pharmacodynamic biomarker is a top priority for the consortium. The CSF consortium is committed to obtaining longitudinal as well as cross-sectional data and, whenever possible, intra-subject test–retest data.

To better understand the contribution of newly synthesized HTT to the HTT pool detected in CSF, CHDI will study the dynamics of HTT production and its half-life in HD patients, similar to studies conducted for amyloid in Alzheimer's disease.<sup>48</sup> Such studies can be done by labeling newly synthesized HTT and then following the output to the CSF. This will require a mass-spectrometer assay that is sensitive enough to measure labeled and unlabeled HTT in femtomolar concentrations; current assays have a limit of detection of 100 pM. We are currently working with contract research organization collaborators to incorporate an immunoprecipitation step to concentrate CSF HTT in order to achieve the required sensitivity. We will then proceed with a flux study to measure the entry of newly synthesized HTT into the CSF.

***Progress points:***

- ***mHTT protein can be measured in CSF from premanifest and manifest HDGECs; however, intra-subject variability over relatively short time periods (1–3 months) still needs to be evaluated.***
- ***Absolute concentration of mHTT in human CSF is very low and the sensitivity to small changes in mHTT concentration is unknown. Furthermore, we currently have limited understanding of the dynamics of production, half-life and origin of the HTT quantified in CSF.***
- ***Evidence suggests an increase in mHTT with disease burden in cross-sectional samples, but this needs replication.***

***4.1.3 Preclinical validation***

Several studies are underway to evaluate the effects of HTT-lowering interventions on mHTT CSF levels in HD preclinical models, in order to validate the measure as a pharmacodynamic biomarker. One major challenge is obtaining a sufficient volume of CSF for the analyses; CHDI's current assay requires 5 µl of rodent HD model CSF for each data point, in triplicate. Pooling of such samples should be avoided due to the risk of blood contamination during the harvesting procedure; therefore, great care must be taken to acquire as much CSF as possible per animal (ideally > 20 µl per animal). We are using two HD models for these studies, the preferred Q175 HET mouse model as well as the BAC HD rat model because of the greater CSF volume it can provide; see section 3.4.1.

It is important that these preclinical studies address whether reducing HTT in specific brain regions will be reflected in the measurable levels of mHTT in the CSF. This is an experimental challenge but the desired area can be selectively treated using specific HTT-lowering agents with well-defined distribution pharmacokinetics. For example, intrastriatal delivery of an AAV-HTT ZFP is being used to lower mHTT in the striatum of Q175 HET mice. Alternatively, intrathecal delivery of an HTT ASO is being used to lower HTT in the spinal cord and cortex of BAC HD rats. We are also delivering the HTT ASO by ICV in both the Q175 HET mouse and the BAC HD rat for a broader distribution and HTT lowering throughout the rodent brain to see whether global lowering is required to observe changes in mHTT levels in the CSF.

Important preliminary results were reported at the 2015 Huntington's Disease Therapeutics Conference. In collaboration with Ionis Pharmaceuticals (then Isis), CHDI analyzed the CSF from HTT ASO-treated BAC HD rats. In the ASO ICV-treated rats, significant decreases in CSF mHTT protein were observed compared



to pre-dose levels ( $p = 0.001$ ), demonstrating that central lowering of mHTT in the rodent brain can result in quantifiable decreases in CSF levels; follow-up studies are planned.

**Progress points:**

- ***mHTT protein can be measured in the CSF of Q175 HET mice and BAC HD rats using the Singulex or MSD assay system.***
- ***Studies are ongoing to evaluate whether CSF levels reflect the amount of mHTT in the region of interest (i.e., striatum, cortex, or other area that received HTT-lowering therapy) in a dose- and time-dependent manner.***

**4.1.4 Biomarker domain status for HTT protein measurement in CSF**

Biological plausibility	<b>High</b>
Technological feasibility	<b>Yes</b>
Measurable in humans	<b>Yes</b>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>Studies ongoing</b> <i>(partial data available)</i>
Signal metrics: dynamic range, variance	<b>Studies ongoing</b> <i>(partial data available)</i>
Measurable in HD animal models	<b>Yes</b>
PoP: Changes in response to central lowering of HTT in animal models	<b>Yes, studies ongoing</b> <i>(partial data available)</i>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>

## 4.2 PET and microPET imaging

PET imaging is a well-established, readily available technique that provides both structural and kinetic information and, compared to other imaging techniques, high sensitivity and high spatial and temporal resolution.<sup>49</sup> Importantly, development of micro-PET instrumentation for small-animal imaging has made this technology appropriate for the quantitative and repetitive imaging of biological function in preclinical models. This approach was selected as the second highest priority because there are already several PET studies showing clinical markers that are clearly expressed in brain regions of interest and are dysregulated in HD.<sup>49-53</sup>

### 4.2.1 Methodology

The main PET tracers being evaluated or under consideration are shown in the table below.

#### *PET tracers being evaluated or under consideration*

<b>Target</b>	<b>PET Ligand</b>	<b>Localization</b>	<b>Preclinical Evaluation Status</b>	<b>Clinical Evaluation Status</b>
D1 receptor	11C-NNC112	Basal ganglia/cortex	<b>Studies completed (uPET)</b>	<i>Currently no planned studies</i>
D2 receptor	11C-raclopride	Striatum/cortex	<b>Studies completed (uPET)</b>	<b>Studies completed and ongoing</b>
PDE10A enzyme	18F-MNI659/ [11C]IMA107	Basal ganglia	<b>Studies completed (uPET)</b>	<b>Studies ongoing and planned</b>
CB1 receptor	18F-FMPEP-d2/ [11C]MePPEP	Basal ganglia/cortex	<b>Studies ongoing (ARG)</b>	<b>Studies completed and planned</b>
5HT2a receptor	11C-MDL100097	Basal ganglia/cortex	<b>Studies completed (uPET)</b>	Studies planned
H3 receptor	11C-GSK189254/ [11C]MK-8278	Basal ganglia/cortex	<b>Studies ongoing (ARG)</b>	Studies planned
Glucose uptake	18F-FDG	Cortex and subcortical	<b>Limited profiling (uPET)</b>	<b>Studies completed and planned</b>
GABA-A receptor	11C-Flumazenil	Basal ganglia/cortex	Studies planned (ARG)	<i>Currently no planned studies</i>
mGluR5 receptor	18F-FPEB	Basal ganglia/cortex	Studies planned (uPET)	<i>Currently no planned studies</i>
M1 receptor	11C-GSK1034702	Basal ganglia/cortex	<i>Currently no planned studies</i>	<i>Currently no planned studies</i>
5HT1a receptor	11C-WAY100635	Cortex	<i>Currently no planned studies</i>	<i>Currently no planned studies</i>
NK1 receptor	18F-FE-SPA-RQ	Basal ganglia/cortex	<i>Currently no planned studies</i>	<i>Currently no planned studies</i>

Other novel PET targets are being explored as a second-tier priority. Extensive qPCR studies were performed by CHDI in collaboration with Dr. Gillian Bates to explore transcriptional changes that occur in the R6/2 and Q175 HET HD model mice at different ages. Both striatal and cortical transcriptional targets

were chosen from published data, RNA sequencing data and, in part, corresponding available translational microPET/PET tracers (i.e., tracers that will bind both mouse and human target orthologs). Those PET tracers that have been used in humans and mice *and* reflect mRNA changes observed in HD model mice compared to WT controls, have been selected for microPET and PET studies.

The ideal PET ligand would be one that targets HTT protein itself. CHDI is currently developing such a ligand and preliminary studies in Q175 HET mice show specificity of signal to HTT lowering; non-human primate pharmacokinetic studies are also planned.

#### *4.2.2 Clinical evaluation*

There is currently one ongoing study in this domain. PEARL-HD is a cross-sectional adaptive-design PET study (associated with a longitudinal study called LONGPET) evaluating the expression of PDE10A enzyme and D2 receptor levels using [<sup>18</sup>F]MNI-659 and [<sup>11</sup>C]raclopride, respectively, in pre-manifest and manifest HDGECs and healthy controls.<sup>54</sup> To date, ten premanifest and five manifest HDGECs (stage I) and fifteen age- and sex-matched control participants have been examined using the aforementioned PET imaging tracers and high-resolution research tomography (a total of 45 subjects will be scanned). The outcome measure is the binding potential (BP<sub>ND</sub>), using a simplified reference tissue model (D2R) and Logan graphical analysis (PDE10A) with the cerebellum as reference region. The regions examined were caudate, putamen, and globus pallidus (GP).

In this study, [<sup>11</sup>C]raclopride and [<sup>18</sup>F]MNI-659 BP<sub>ND</sub> were significantly lower in HDGECs compared with controls. In manifest stage I participants, the mean BP<sub>ND</sub> reduction (vs. control) for D2R and PDE10A availability, respectively, was 63% and 91% in the caudate, 43% and 69% in the putamen and 25% and 65% in the GP. In premanifest participants, the corresponding reductions were 32% and 53% in the caudate, 31% and 43% in the putamen, and 16% and 41% in the GP. These results show that striatal PDE10A is already more severely reduced than striatal D2R in HD, at the earliest stages of HD examined.

Russell et al. examined PDE10A levels in eleven premanifest and manifest HDGECs and nine healthy controls using [<sup>18</sup>F]MNI-659. Compared to controls, the HDGEC cohort had significantly lower striatal [<sup>18</sup>F]MNI-659 uptake (mean difference, -48.4%; P < 0.001).<sup>55</sup> Striatal [<sup>18</sup>F]MNI-659 uptake correlated strongly with severity of disease as measured by the clinical scale (UHDRS Motor subscale; R = 0.903; P <

0.001), burden of pathology as measured by age  $\times$  [CAG repeats – 35.5] (BOP;  $R = 0.908$ ;  $P < 0.001$ ), and regional atrophy ( $R = 0.667$ ;  $P < 0.05$ ).

Additional PET studies are planned, one of which will assess PDE10A binding in a larger cohort of HDGECs to better understand the observed variability in binding potential and get a better understanding of the effect size. This study will also be the first to evaluate histamine H3 receptor levels using [18F]FMH3 in HDGECs. H3 therapeutics have shown promise in the treatment of memory and cognitive performance<sup>56,57</sup> and are presumed to be involved in HD. Indeed, the hypothalamic tuberomamillary nucleus (from where all histamine neurons originate<sup>58</sup>) contains the highest density of nuclear and cytoplasmic inclusions of mHTT.<sup>59</sup> Autoradiographic examination of postmortem HD brains has indicated lower H3 receptor levels in the caudate (–69%), putamen (–77%) and pallidum (–80%) compared to controls, suggesting involvement of the H3 receptor in the pathophysiology of HD.<sup>60</sup> Inclusion of this target will provide additional information on H3 receptor availability and assess the utility of [18F]FMH3 as a potential imaging biomarker.

Another study in the planning stages, PETMARK-HD, will characterize potential longitudinal progression and pharmacodynamic biomarkers in substantial participant cohorts of early premanifest to early manifest HD and matched healthy controls. Multiple PET targets will be imaged longitudinally over a 4-year period to provide a corticostriatal ‘signature’ of disease progression. PET targets include PDE10A, H3R, 5HT2AR and CB1R, assessed using [11C]JMA107, [11C]MK-8278, [11C]MDL100907 and [11C]MePPEP ligands, respectively. The PETMARK-HD study will establish a series of 6-month PET readouts describing multi-target pathologic change from premanifest to early HD; this temporal feature will facilitate evaluation over intervals relevant to future investigational studies. MRI structural and diffusion data will be combined with PET to perform connectivity-based functional analyses of target expression; the study will also correlate PET volumetric and metabolic changes with clinical data across the different stages of HD.

***Progress points:***

- ***All PET ligands currently being evaluated as potential biomarkers in animal models are being used clinically. For some (raclopride and MNI-659), we have acquired detailed data in HDGECs; for others it is not known how the disease affects the expression of the target and therefore whether the PET imaging is consistently measurable in HD patients.***
- ***PET signals are robust and can be assessed in multi-site trials. However, evaluation of required effect size, longitudinal reliability, and inter-subject variability for each ligand is ongoing.***
- ***Cross-sectional differences in PDE10A, CB1, D2, and D1 are established and longitudinal assessment is ongoing to address alterations during disease progression. Work is also ongoing to establish the utility of new targets such as 5HT2A and H3.***

***4.2.3 Preclinical validation***

***4.2.3.1 Longitudinal microPET imaging of the Q175 HET mouse model***

Male heterozygous Q175 and WT animals were imaged in a longitudinal fashion to assess D1, D2, 5HT2A and PDE10A ligand binding at 6 and 9 months of age using nanoScan® PET/MRI and nanoScan® PET/CT scanners (Mediso Ltd., Hungary).

At 6 months of age, the BP<sub>ND</sub> in the striatum was lower in Q175 mice compared to WT by 40% in the case of D2 receptors ( $P < 0.0001$ ), by 52% in the case of PDE10A ( $P < 0.001$ ), by 29% in the case of D1 receptors ( $P < 0.001$ ), and by 12% in the case of 5HT2A receptors ( $P < 0.01$ ). In the rostral cortex, D1-receptor binding was 24% lower in Q175 mice compared to WT. In the hippocampus, the BP<sub>ND</sub> of 5HT2A receptors in Q175 mice was 12% lower compared to WT. At 9 months, there was a slight additional reduction of D1, D2 and 5HT2A in the striatum compared to 6 months (with a 4–7% further decrease in Q175 compared to WT), whereas PDE10A reached a plateau after 6 months (i.e., similar levels at 9 months). Cortical markers D1 and 5HT2A were also slightly further decreased at 9 months in Q175 mice (up to 20%). These results suggest that the proteins measured by microPET may be useful downstream markers to validate the effect of HTT-lowering therapies in HD animal models.

#### 4.2.3.2 Longitudinal effect of lowering mHTT with ZFPs on the expression of dopamine D2 receptor and PDE10A enzyme in the striatum of Q175 mice, as measured by microPET

The primary preclinical study to evaluate whether intrastriatal injections of ZFPs affect striatal dopamine (D2 and D1) receptor and PDE10A expression in the Q175 mouse model uses the so-called reversal treatment paradigm of intervention after the appearance of the disease phenotype. In this paradigm, AAV-HTT ZFP, a repressor of mutant HTT, was unilaterally injected into the striatum of 4-month-old Q175 mice (i.e., at an age when loss of D2 and PDE10A has already begun). The contralateral non-injected hemisphere was used as an intra-subject control. In addition, another group of 4-month-old Q175 mice received unilateral intrastriatal injections of the control AAV-GFP construct. All animals were longitudinally imaged at 7 and 10 months of age using [<sup>11</sup>C]-raclopride (D2 receptor) and [<sup>18</sup>F]-MNI 659 (PDE10A) ligands in high-resolution MRI-microPET. This experiment demonstrated 12% and 15% improvement in PDE10A ligand BP<sub>ND</sub> at 7 and 10 months of age, respectively, in HTT ZFP repressor injected striatum compared to non-injected striatum; this improvement was not observed in a control Q175 cohort. In contrast, no improvement of D2 receptor BP<sub>ND</sub> was observed. While these results need to be repeated, they do indicate that an increase of [<sup>18</sup>F]-MNI 659 binding to PDE10A could potentially be used to indicate HTT lowering.

We are testing another intervention paradigm (prevention), in which we treat 2-month-old Q175 mice with unilateral intrastriatal injections of AAV-HTT ZFP repressor; we plan to analyze D2 and PDE10A ligand binding in these mice at 5 months of age.

#### 4.2.3.3 Development of HTT-directed PET tracer

Work is ongoing to develop an HTT-directed PET tracer to measure HTT levels in specific brain regions. Using amyloid-binding ligands from Alzheimer's disease research as starting points (which themselves were poor binders to HTT aggregates) and a number of *in vitro* assay systems to detect and quantify binding of ligands to HTT aggregates, medicinal chemistry efforts have significantly modified and matured several small-molecule compound series.

In autographic radioligand binding analyses, several lead compounds have displayed significantly greater binding to mHTT and/or aggregates in specific regions of the brain from mouse HD models (e.g., striatum, cortex, hippocampus) and human HD postmortem samples (e.g., insula, thalamus) compared to analogous regions in WT mice and non-HD controls. We are also using high-resolution microscopic emulsion

autoradiography, combining autographic binding and immunohistochemistry (using the HTT-aggregate recognizing antibody EM48) to follow radioligand binding and HTT aggregate-specific immunoreactivity. Results to date have shown clusters of silver grains (representing radioligand) selectively co-localized with EM48 immunoreactive HTT aggregates; neither silver grains nor EM48 immunoreactivity were detected in the WT sections.

Also, a lead compound, when tested *in vivo* via tail vein administration of radioligand, exhibited rapid and robust uptake in Q175 HOM HD mice compared to only marginal uptake in WT controls. Additional studies are now ongoing to radiolabel such compounds with <sup>11</sup>C to allow micro-PET and PET imaging in HD mice and non-human primates, respectively. This would help define regional distribution, specific uptake, kinetics and non-specific binding. Analogous lowering paradigms are being used to test the HTT-directed radioligands (data analysis using ARG is in progress in Q175 mice treated with AAV-ZFPs).

***Progress points:***

- ***The expression of PDE10A and D1, D2 and 5HT2A receptors has been observed using microPET imaging in the Q175 HET mouse HD model.***
- ***Lowering of HTT in striatum using AAV-HTT ZFP resulted in significant 12–15% increases in PDE10A binding potential in 7- and 10-month old Q175 HET mice measured 3 and 6 months after treatment, as demonstrated by microPET. However, no significant change in binding potential was observed in the above paradigm for dopamine D2 receptor, suggesting that biomarker changes in response to HTT lowering may be protein-specific under certain paradigms.***

#### 4.2.4 PET imaging (other than HTT) biomarker domain status

Biological plausibility	<b>Moderate</b>
Technological feasibility	<b>Yes</b>
Measurable in humans	<b>Yes</b>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>Studies ongoing</b> <i>(partial data available)</i>
Signal metrics: dynamic range, variance	<b>Studies ongoing</b> <i>(uncertain)</i>
Measurable in HD animal models	<b>Yes</b>
PoP: Changes in response to central lowering of HTT in animal models	<b>Yes</b>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>

#### 4.2.5 HTT PET imaging biomarker domain status

Biological plausibility	<b>High</b>
Technological feasibility	<b>Unknown</b>
Measurable in humans	<b>Studies ongoing</b> <i>(uncertain)</i>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>TBD</b>
Signal metrics: dynamic range, variance	<b>Studies ongoing</b> <i>(uncertain)</i>
Measurable in HD animal models	<b>Studies ongoing</b> <i>(uncertain)</i>
PoP: Changes in response to central lowering of HTT in animal models	<b>Studies planned</b>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>



### 4.3 Quantitative EEG

EEG measurements are a reflection of brain electrical activity with millisecond temporal resolution, and are the most direct and non-invasive correlate of brain processing. As a technique, qEEG has the advantages of being relatively affordable and easily obtainable, although the technique's reliability depends heavily on well-trained technicians. It can also be performed in both small and large animal models.

EEG signals result from the functioning of the cortex in its full complexity. Many types of insults alter EEG readouts, which are also sensitive to a number of medications and mind-altering states. Importantly, there is evidence supporting EEG abnormalities in HD patients such as decreases in absolute alpha power in both manifest and premanifest HDGECs.<sup>61</sup> Differences in oscillatory synchrony—both spatially across the brain as well as across the frequency spectrum—have also been shown to correlate with disease severity, cognitive dysfunction, total functional capacity, and CAG length.<sup>62</sup>

Due to the large number of background conditions that must be standardized in order to detect a sub-acute or chronic drug effect, the technique may have a lower degree of reliability. As such, EEG is a second-tier priority, but we are committed to assessing its potential because it is currently one of the few windows available to evaluate effects at the level of the cortex.

#### *4.3.1 Methodology*

EEG is the measurement, using digital technology, of electrical patterns at the surface of the scalp, which primarily reflect cortical electrical activity. qEEG is the mathematical processing of digitally recorded EEG to highlight specific waveform components, transform the EEG into a format or domain that elucidates relevant information, or associate numerical results with the EEG data for subsequent review and comparison. These techniques provide a neurophysiological approach to viewing the dynamic changes taking place throughout the brain (e.g., while performing a cognitive task). Subjects are always tested in the awake resting state (the clinical norm). Outcomes of interest include global spectra power, inter-hemispheric coherence and power spectra per hemisphere.

#### *4.3.2 Clinical evaluation*

Two clinical studies of this domain are in planning and aim to characterize qEEG alterations in the context of premanifest and manifest HDGECs. The first planned study is designed to characterize the patterns of

qEEG in HDGECs as compared to controls. The acquisition of data is standardized to allow the prospective meta-analysis of the two datasets. One pilot study evaluating whether a change in the qEEG signature can be identified in premanifest and early-manifest HDGECs has already been completed.<sup>62</sup> In this study, all HDGEC groups showed an increase in global delta power, and loss of the normal anterior–posterior gradient of relative alpha and delta power. Relative alpha power gradient loss correlated with lower total functional capacity (TFC) scores, greater cognitive dysfunction and increased CAG repeats.<sup>62</sup> The second study is more complex and aims to assess the potential of several imaging modalities including FDG-PET and fMRI (both BOLD and ASL) to identify signature networks in the ‘connectome’ that can be specifically linked to HD to confirm and expand previous work<sup>63-65</sup>. qEEG is an optional measurement in this protocol and we expect that a sufficient number of participants will consent to undergo qEEG, thereby contributing to the further characterization of the metrics of this measurement. Additionally, the co-registration of imaging and qEEG will allow a better understanding of the qEEG patterns.

***Progress points:***

- ***qEEG can be measured in HD patients.***
- ***qEEG is sensitive to change, acutely to the action of different psychotropic drugs. Signals are generally robust and reliable; however, it is currently unknown whether lowering HTT will alter the qEEG signal.***
- ***Studies have shown an increase in global delta power, and loss of normal anterior-posterior gradient of relative alpha and delta power in HDGECs vs. control subjects.***

**4.3.3 Preclinical validation**

There are currently two preclinical studies planned in which the Q175 HET HD mouse model will be used to evaluate the effect of HTT-lowering interventions on qEEG readings, and both are designed to test the effect of an intervention after the appearance of a disease phenotype. Specifically, HTT ASOs are being used to treat the brain more globally by ICV bolus dosing and HTT ZFPs are being used to selectively treat the striatum.

**Progress points:**

- ***qEEG can be used in both mouse and rat preclinical HD models.***
- ***PoP studies to assess whether qEEG signals change in response to HTT lowering in a dose- and time-dependent manner are planned to start in Q1 2015.***

**4.3.4 qEEG biomarker domain status**

Biological plausibility	<b>Moderate</b>
Technological feasibility	<b>Yes</b>
Measurable in humans	<b>Yes</b>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>Yes</b>
Signal metrics: dynamic range, variance	<b>Yes</b>
Measurable in HD animal models	<b>Yes</b>
PoP: Changes in response to central lowering of HTT in animal models	<b>Studies planned</b>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>

#### 4.4 Proteomics: static and kinetic

This biomarker domain focuses on proteins other than HTT in the CSF and is also considered a second-tier priority. Measurement of protein levels and/or protein flux in the CSF may allow us to detect changes resulting from an HTT-lowering treatment. There are two ways to measure such proteins, either at steady-state levels (static) or in a time-dependent manner (dynamic). For the former, changes in the absolute concentration of one or more proteins in the CSF can be readily measured using either established immunoassays or newer proteomic techniques such as selected reaction monitoring (SRM) or multiple reaction monitoring (MRM). These techniques are now routinely used to identify proteins that change under pathologic or treatment conditions.

##### 4.4.1 Methodology

###### 4.4.1.1 Static

There is now an SRM assay available for every protein in the human proteome. This approach has attained relative success in therapeutic areas such as Alzheimer's disease<sup>66</sup> and multiple sclerosis<sup>67</sup> where SRM and MRM have been used to assess 10s of proteins simultaneously and to identify those that are quantifiably distinguishable between patients and healthy controls (i.e., diagnostic biomarkers). For the SRM/MRM approach to work in biomarker development, it will be important to focus on proteins that have human and rodent orthologs to enable the relevant preclinical studies. To identify the more accessible biomarkers, studies should be carried out in both CSF and plasma, while brain tissue can also be examined in initial preclinical studies to identify protein changes. A critical consideration in identifying and validating proteins that are altered by HTT-lowering treatment is the quality of the tissue source. For CSF, samples should be acquired and processed in a state-of-the-art, standardized way, minimizing blood contamination as well as food and drug effects.

###### 4.4.1.2 Dynamic

Another approach is the analysis of dynamic proteomics by measuring molecular fluxes within cellular processes and pathways. The method proposed involves the use of stable isotope labeling of vesicle cargo molecules (following a period of administration of heavy water,  $^2\text{H}_2\text{O}$ ), and observation of the appearance and disappearance of labeled cargo molecules in CSF as a kinetic marker. This is a proprietary technology developed by Kinemed. Specifically, the method involves measuring the time course of labeled cargo protein release into the CSF following synthesis in the cell body. After *in vivo* labeling of protein cargo

molecules, a time course of appearance and disappearance of these labeled cargo molecules in the CSF (as a fraction of total, unlabeled protein) is calculated.

#### *4.4.2 Clinical evaluation*

##### *4.4.2.1 Static*

Previous proteomic discovery studies in blood and CSF samples from HD patients at various disease stages have identified a potential hot-list of molecules that were differentially expressed either between controls and HD patients, between patients at different stages of the disease, or over time within subjects. To identify which of these proteins might serve as pharmacodynamic biomarkers to detect the effects of an HTT-lowering therapy, we refined this list with data from mouse models treated with HTT-lowering agents. Since those animal studies assessed changes to the transcriptome, rather than the proteome, and used brain tissue rather than CSF, we limited the search to transcripts that coded for secreted proteins, which are more likely to be released into the CSF. We further refined the list by prioritizing proteins that either already have a readout/assay (i.e., immunoassay) or are considered amenable to assay development. Other proteins under consideration include those expressed at high levels in the brain (particularly the cortex, striatum and cerebellum) and secretome-enriched proteins, such as brain-derived neurotrophic factor (BDNF) and enkephalin. Using this approach we have identified a prioritized set of candidate proteins that could be assessed in preclinical or clinical samples for their utility as pharmacodynamic biomarkers following HTT-lowering interventions.

Among the prioritized candidate proteins on the hot-list for initial study are proENK, complement (C1qb; C1qc; C4b), BDNF, apoE, cathepsin D, clusterin, and neurofilament light chain. The expression of these proteins will be assessed in the new HD CSF collection, HDClarity. In addition, a new hypothesis-free proteomic discovery approach will also be conducted on this new collection.

***Progress points:***

- ***All proteins being explored for static measures have been measured in human CSF, and most in HD CSF.***
- ***Studies are planned to determine how robust the readouts are in HD CSF.***
- ***Many of the proteins being explored in the static measures have shown some trend of cross-sectional difference in mass-spectrometry-based assays.***

***4.4.3 Preclinical validation***

Several studies are currently evaluating the effects of HTT-lowering interventions on static and dynamic protein expression. These mainly employ the Q175 HET mouse model, but earlier studies have also used the R6/2 transgenic line. The main interventions under investigation are HTT ASOs given by ICV bolus dosing after the appearance of a disease phenotype, which would mimic a manifest intervention.

***4.4.3.1 Static***

Plans are underway to evaluate changes in the concentrations of a prioritized list of proteins including proENK, complement (C1qb; C1qc; C4b), BDNF, apoE, cathepsin D, clusterin, neurofilament light chain, among others, in the CSF of Q175 HET mice. A longer list of proteins is available based on proteomic discovery studies using human HD CSF samples, HTT biology, and transcriptomic changes in HD animal models following HTT-lowering treatments, and could be the basis for a broader SRM/MRM approach to extend the earlier findings.

***4.4.3.2 Dynamic***

Dynamic proteomics has largely relied upon a pulse-chase paradigm using deuterated water, which has proven safe for both animal and human applications. CHDI conducted several studies with Kinemed, which explored microtubule dynamics in brains and CSF marker flux changes in HD mouse models. To date, dynamic proteomic studies have revealed: (1) Altered CSF kinetics (both appearance and disappearance) in R6/2 mice of the neuronal cargo proteins neuregulin-1 and sAPP $\alpha$ , but not for chromogranin B, and (2) altered microtubule dynamics (microtubule hyperdynamicity) in the R6/2 and Q175 HET HD models that was age-dependent and region-specific (found in striatum and cortex but not cerebellum), suggesting a mechanistic link for the observed altered CSF kinetics.

**Progress points:**

- **Some of the proteins have already been measured in both static and dynamic studies.**

**4.4.4 Proteomics static biomarker domain status**

Biological plausibility	<b>Moderate</b>
Technological feasibility	<b>Yes</b>
Measurable in humans	<b>Yes</b>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>Studies ongoing</b> <i>(partial data available)</i>
Signal metrics: dynamic range, variance	<b>Studies ongoing</b> <i>(partial data available)</i>
Measurable in HD animal models	<b>Studies ongoing</b> <i>(partial data available)</i>
PoP: Changes in response to central lowering of HTT in animal models	<b>Studies planned</b>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>

**4.4.5 Proteomics dynamic biomarker domain status**

Biological plausibility	<b>Moderate</b>
Technological feasibility	<b>Yes</b>
Measurable in humans	<b>Yes</b>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>TBD</b>
Signal metrics: dynamic range, variance	<b>TBD</b>
Measurable in HD animal models	<b>Yes</b>
PoP: Changes in response to central lowering of HTT in animal models	<b>TBD</b>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>

## 4.5 Magnetic Resonance Spectroscopy (MRS) imaging

MRS is a non-invasive method that enables the quantification of metabolites in samples. Compared with other modalities, it is inexpensive, rapidly conducted, widely accessible (it uses clinical MRI equipment), and can be used in both clinical and preclinical settings. It can also be used to evaluate multiple tissue types simultaneously (e.g., grey and white matter). In our program, MRS is under study as a second-tier priority.

### 4.5.1 Methodology

MRS allows the detection of relatively small molecules, typically in concentrations of 0.5–10 mM, within cells or in extracellular spaces. The determined MR spectra provides information on metabolic pathways and changes therein. Attention has focused on proton ( $^1\text{H}$ ) and phosphorus ( $^{31}\text{P}$ ) MRS, and studies have been conducted using either single voxels or many voxels simultaneously. The main brain regions of interest include the striatum and cortex. In clinical studies the typical field strength of the MRS systems is 3T, but in very particular and circumscribed paradigms, MR systems with field strength higher than 3T (including 7.0 T systems) are used for optimum signal-to-noise ratios. However this option very much limits the clinical feasibility of the technique and it is therefore a research option rather than an implementable solution in multi-site clinical trials.

Suitable brain metabolites for clinical HD studies include:

- NAA: N-acetyl-aspartate, contained only in neurons, serves as healthy neuronal marker. Measurements of total NAA include N-acetyl-aspartyl-glutamate (NAAG).
- GLU: Glutamate, also GLX (glutamate + glutamine); Glutamate is a neurotransmitter and glutamine is involved in neurotransmitter synthesis.
- CR: Creatine/phosphocreatine buffer ATP concentrations.
- CHO: Choline groups are found in acetylcholine and in membrane breakdown products.
- MI: Myo-inositol is a glial cell marker.

The MRS technique may be particularly attractive for studying the cortex since a cortical-focused voxel can be utilized.



#### 4.5.2 Clinical evaluation

MRS was evaluated in a subset of control, premanifest and early manifest HD subjects taking part in the TRACK-HD and Track-On clinical studies.<sup>68, 69</sup> MRS measures with a putaminal voxel were conducted annually for 4 years at a single clinical site. An additional clinical site and the inclusion of a second voxel, in the cortex, were incorporated in the last 3 years.

Analysis of the final year is still ongoing, but the data clearly show that the MRS signal in HD is robust and reliable, both over time and across sites, at least when similar scanners are used. The data also demonstrate that the MRS signal for NAA was lower in both premanifest and manifest HDGECs than controls, while the signal for myo-inositol was higher in manifest HDGECs than premanifest HDGECs and controls.<sup>68</sup> So while the ability of the MRS signal to serve as an HTT-lowering biomarker remains to be demonstrated, this measure could be employed in HD clinical trials using an already-established methodology. Because of the ability to selectively focus on the cortex or putamen, this may be particularly attractive for interventions expected to have limited brain coverage.

CHDI has two additional MRS clinical studies that are mechanistically investigating the energetics pathways and the potential compromise of mitochondrial energy fluxes in HD. These studies were not planned as biomarker studies but might provide some insight into the clinical utility of MRS as a biomarker in HD.

#### ***Progress points:***

- ***<sup>1</sup>H-MRS can be performed in HD patients, focusing on cortex and/or putamen.***
- ***The MRS signal is robust and reliable. The use of MRS in multi-site studies is still challenging since combining data from different scanner types is not standardized; developing this standardization is planned. However, it is currently unknown whether HTT-lowering interventions will alter the signal.***
- ***Studies have shown NAA to be lower in premanifest and manifest HDGECs than controls, and myo-inositol is higher in manifest HDGECs than premanifest HDGECs or controls.***

#### 4.5.3 Preclinical validation

There are currently several ongoing and planned studies to evaluate HTT-lowering interventions on MRS measures. Interventional studies are based on the Q175 HET mouse model, but the R6/2 transgenic line and the BAC HD rat model have also been employed in non-interventional MRS optimization studies. Treatment paradigms include ICV bolus HTT ASO as well as intrastriatal administration of HTT ZFPs and HTT siRNAs to lower HTT. The main intervention being tested is after the appearance of a disease phenotype in the rodent model, to mimic manifest intervention.

Additionally, based on recent results in Q175 HET mice showing a progressive decrease in the glutamatergic and GABAergic TCA cycle in neurons, another preclinical study is being planned using HTT-lowering agents. The study aims to test whether brain function and energy metabolism using MRS measures of the glutamate/glutamine cycle, and neuronal and astrocytic mitochondrial TCA cycle fluxes, can be restored through HTT lowering.

**Progress points:**

- ***<sup>1</sup>H-MRS can be measured in Q175 HET preclinical HD models.***
- ***Studies are ongoing to see whether <sup>1</sup>H-MRS signals change in response to HTT lowering in a dose- and time-dependent manner.***

#### 4.5.4 MRS biomarker domain status

Biological plausibility	<b>Moderate</b>
Technological feasibility	<b>Yes</b>
Measurable in humans	<b>Yes</b>
Repeatable within subjects	<b>Yes</b>
Reliably measured in HDGECs	<b>Yes</b>
Signal metrics: dynamic range, variance	<b>Yes</b>
Measurable in HD animal models	<b>Yes</b>
PoP: Changes in response to central lowering of HTT in animal models	<b>Studies ongoing</b> <i>(partial data available)</i>
Changes in response to an HTT-lowering intervention in HDGECs	<b>TBD</b>



## 5. CLOSING COMMENTS

Identifying easily measured, reliable, and robust pharmacodynamic biomarkers of dynamic changes in HTT protein levels in the brain is essential for the development and evaluation of potential HTT-lowering interventions. CHDI is committed to its ongoing HTT-Lowering Biomarker Initiative to support upcoming HTT-lowering clinical trials. The program is based on a series of pragmatic and scientific decisions ranging from the pre-defined criteria required for a suitable biomarker, to prioritization of candidate biomarkers, to the choice of animal models used for preclinical validation. These decisions have been made to not only ensure that the program is at the forefront of technology but also that the goals are realistic and can be met within a reasonable timeframe. By working in close collaboration with a large number of commercial and academic colleagues, the initiative has brought together new ideas and methods from other therapeutic areas and applied them specifically to HD.

The CHDI HTT-Lowering Biomarker Initiative has already achieved much; for each of the biomarker candidates we have a better understanding of how they behave in HD and the robustness of signal. However, we are humbly aware of the challenge of identifying and fully characterizing biomarkers that can successfully and accurately track the lowering of HTT in the human brain. It is an ongoing effort, and we are committed to providing regular and timely updates on the progress made.

## 6. REFERENCES

1. Godinho BM, Malhotra M, O'Driscoll CM, Cryan JF. Delivering a disease-modifying treatment for Huntington's disease. *Drug Discov Today*. 2015;20(1):50-64.
2. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: what's in the pipeline? *Mov Disord*. 2014;29(11):1434-1445.
3. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. *Neuron*. 2012;74(6):1031-1044.
4. Magen I, Hornstein E. Oligonucleotide-based therapy for neurodegenerative diseases. *Brain Res*. 2014;1584:116-128.
5. Garriga-Canut M, Agustin-Pavon C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. *Proc Natl Acad Sci U S A*. 2012;109(45):E3136-3145.
6. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. *Proc Natl Acad Sci U S A*. 2005;102(16):5820-5825.
7. Martinez T, Wright N, Lopez-Fraga M, Jimenez AI, Paneda C. Silencing human genetic diseases with oligonucleotide-based therapies. *Hum Genet*. 2013;132(5):481-493.
8. Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. *Hum Gene Ther*. 2014;25(5):461-474.
9. Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. *Mol Ther*. 2011;19(12):2169-2177.
10. Yu D, Pendergraft H, Liu J, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. *Cell*. 2012;150(5):895-908.
11. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell*. 1993;72(6):971-983.
12. Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington's disease gene (IT15) protein product. *Neuron*. 1995;14(5):1065-1074.
13. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurol*. 2009;8(9):791-801.
14. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. *Physiol Rev*. 2010;90(3):905-981.
15. Trottier Y, Biancalana V, Mandel JL. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. *J Med Genet*. 1994;31(5):377-382.
16. Walker FO. Huntington's Disease. *Semin Neurol*. 2007;27(2):143-150.
17. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *Lancet Neurol*. 2012;11(1):42-53.
18. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. *Biochem J*. 2008;412(2):191-209.
19. Borowsky B, Sampaio C. Experimental therapeutics in huntington's disease : moving forward in clinical trials. In: Bates G, Tabrizi S, Jones L, eds. *Huntington's disease, 4th edition*. Oxford: Oxford University Press,; 2014.

20. Harper SQ. Progress and challenges in RNA interference therapy for Huntington disease. *Arch Neurol*. 2009;66(8):933-938.
21. Zhang HS, Zeitler B, Froelich S, et al. Engineering zinc finger transcriptional repressors selectively inhibit mutant huntingtin expression and reverse disease phenotypes in Huntington's disease patient-derived neurons and in rodent models. Abstract presented at Society for Neuroscience (SFN) 014, Washington, DC. November 15-19, 2014. . 2014.
22. Sussmuth SD, Haider S, Landwehrmeyer GB, et al. An Exploratory Double blind, Randomised Clinical Trial with Selisistat, a SirT1 Inhibitor, in Patients with Huntington's Disease. *Br J Clin Pharmacol*. 2014.
23. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet*. 2004;36(6):585-595.
24. Smith MR, Syed A, Lukacsovich T, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. *Hum Mol Genet*. 2014;23(11):2995-3007.
25. Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. *Clin Genet*. 2014;86(1):29-36.
26. Gagnon KT, Pendergraff HM, Deleavey GF, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. *Biochemistry*. 2010;49(47):10166-10178.
27. Southwell AL, Skotte NH, Kordasiewicz HB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. *Mol Ther*. 2014;22(12):2093-2106.
28. Hu J, Liu J, Yu D, et al. Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. *Nucleic Acid Ther*. 2014;24(3):199-209.
29. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. *J Clin Invest*. 2011;121(2):500-507.
30. Ramaswamy S, Kordower JH. Gene therapy for Huntington's disease. *Neurobiol Dis*. 2012;48(2):243-254.
31. Ferlini A, Scotton C, Novelli G. Biomarkers in rare diseases. *Public Health Genomics*. 2013;16(6):313-321.
32. Dienstmann R, Rodon J, Tabernero J. Biomarker-driven patient selection for early clinical trials. *Curr Opin Oncol*. 2013;25(3):305-312.
33. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. *Cancer J*. 2009;15(5):406-420.
34. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. *Mol Interv*. 2007;7(6):325-334.
35. MacLeod R, Tibben A, Frontali M, et al. Recommendations for the predictive genetic test in Huntington's disease. *Clin Genet*. 2013;83(3):221-231.
36. Morton AJ, Howland DS. Large genetic animal models of Huntington's Disease. *J Huntingtons Dis*. 2013;2(1):3-19.
37. Menalled LB. Knock-in mouse models of Huntington's disease. *NeuroRx*. 2005;2(3):465-470.
38. Vlamings R, Zeef DH, Janssen ML, et al. Lessons learned from the transgenic Huntington's disease rats. *Neural Plast*. 2012;2012:682712.
39. Kim J, Bordiuk OL, Ferrante RJ. Experimental models of HD and reflection on therapeutic strategies. *Int Rev Neurobiol*. 2011;98:419-481.
40. Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. *Nat Rev Neurosci*. 2013;14(10):708-721.

41. Heikkinen T, Lehtimäki K, Vartiainen N, et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and <sup>1</sup>H MRS in zQ175 knock-in mouse model of Huntington's disease. *PLoS One*. 2012;7(12):e50717.
42. Menalled LB, Kudwa AE, Miller S, et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. *PLoS One*. 2012;7(12):e49838.
43. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, et al. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. *J Neurosci*. 2012;32(44):15426-15438.
44. Deverman BE, Simpson BP, Pravdo PL, et al. Novel adeno-associated viruses engineered for efficient and widespread CNS transduction. Poster presented at Hereditary Disease Foundation Meeting, Boston, MA, 2014.
45. Wild E, Robertson D, Miller J, et al. Quantifying mutant Huntingtin in Huntington's disease CSF. *J Neurol Neurosurg Psychiatry*. 2014;85e4 doi:10.1136/jnnp-2014-309236.23
46. Wild E, Baggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. *J Clin Invest*. 2015;In press.
47. Macdonald D, Tessari MA, Boogaard I, et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins. *PLoS One*. 2014;9(5):e96854.
48. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. *Arch Neurol*. 2012;69(1):51-58.
49. Niccolini F, Politis M. Neuroimaging in Huntington's disease. *World J Radiol*. 2014;6(6):301-312.
50. Antonini A, Leenders KL, Eidelberg D. [<sup>11</sup>C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. *Ann Neurol*. 1998;43(2):253-255.
51. Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. *Brain*. 1997;120 ( Pt 3):503-514.
52. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. *Brain*. 1995;118 ( Pt 3):689-696.
53. Pavese N, Politis M, Tai YF, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. *Neurobiol Dis*. 2010;37(2):356-361.
54. Fitzner-Attas C, Fazio P, Mrzljak L, et al. Imaging of phosphodiesterase 10A (PDE10A) enzyme and D2 receptor levels in the living brain of Huntington's disease gene expansion carriers and healthy controls (Abstract). *Mov Disord*. 2014;29 (Suppl 1):S207-208.
55. Russell DS, Barret O, Jennings DL, et al. The Phosphodiesterase 10 Positron Emission Tomography Tracer, [<sup>18</sup>F]MNI-659, as a Novel Biomarker for Early Huntington Disease. *JAMA Neurol*. 2014;71(12):1520-1528.
56. Baronio D, Gonchoroski T, Castro K, Zanatta G, Gottfried C, Riesgo R. Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. *Ann Gen Psychiatry*. 2014;13(1):34.
57. Shan L, Bao AM, Swaab DF. The human histaminergic system in neuropsychiatric disorders. *Trends Neurosci*. 2015.
58. Blandina P, Munari L, Provensi G, Passani MB. Histamine neurons in the tuberomammillary nucleus: a whole center or distinct subpopulations? *Front Syst Neurosci*. 2012;6:33.
59. Aziz A, Fronczek R, Maat-Schieman M, et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. *Brain Pathol*. 2008;18(4):474-483.
60. Goodchild RE, Court JA, Hobson I, et al. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. *Eur J Neurosci*. 1999;11(2):449-456.

61. Nguyen L, Bradshaw JL, Stout JC, Croft RJ, Georgiou-Karistianis N. Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions. *Brain Res Rev.* 2010;64(1):177-194.
62. Hunter A, Bordelon Y, Cook I, Leuchter A. QEEG Measures in Huntington's Disease: A Pilot Study. *PLoS Curr.* 2010;2:RRN1192.
63. Tang CC, Feigin A, Ma Y, et al. Metabolic network as a progression biomarker of premanifest Huntington's disease. *J Clin Invest.* 2013;123(9):4076-4088.
64. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. *Trends Neurosci.* 2009;32(10):548-557.
65. Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. *J Nucl Med.* 2001;42(11):1591-1595.
66. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol.* 2010;6(3):131-144.
67. Jia Y, Wu T, Jelinek CA, et al. Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). *Clin Proteomics.* 2012;9(1):9.
68. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. *Neurology.* 2010;75(19):1702-1710.
69. Sturrock A, Laule C, Wyper K, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. *Mov Disord.* 2015;30(3):393-401.